Patents by Inventor Kevin R. Leiby

Kevin R. Leiby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020155499
    Abstract: The invention provides isolated nucleic acids molecules, designated 32624 nucleic acid molecules, which encode novel UDP-glucuronosyl and glycosyl transferase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32624 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32624 gene has been introduced or disrupted. The invention still further provides isolated 32624 proteins, fusion proteins, antigenic peptides and anti-32624 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: September 25, 2001
    Publication date: October 24, 2002
    Inventor: Kevin R. Leiby
  • Publication number: 20020123475
    Abstract: The invention provides isolated nucleic acids molecules, designated 32626 nucleic acid molecules, which encode novel UDP-glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32626 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32626 gene has been introduced or disrupted. The invention still further provides isolated 32626 proteins, fusion proteins, antigenic peptides and anti-32626 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 29, 2001
    Publication date: September 5, 2002
    Inventors: Kevin R. Leiby, Frank Spaltmann, William James Cook
  • Publication number: 20020058800
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention describes a gene known in the art, alternatively, as ST2, T1 and Fit-1, and referred to herein as the 103 gene. The 103 gene is disclosed herein to be differentially expressed in TH2 cells and not in TH1 cells. Further, the 103 gene product is demonstrated herein to be an important modulator of TH2 and TH2-like immune response both in vitro and in vivo. Thus, the 103 gene, its gene products and antibodies that specifically bind thereto can be used diagnostically or as targets for therapeutic intervention in the treatment of a variety of immune disorders.
    Type: Application
    Filed: July 6, 2001
    Publication date: May 16, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Gillian A. Kingsbury, Kevin R. Leiby
  • Publication number: 20020055139
    Abstract: The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 1, 2001
    Publication date: May 9, 2002
    Inventors: Douglas A. Holtzman, John D. Sharp, Kevin R. Leiby, Steven Bossone, Yang Pan, Thomas M. Barnes, Christopher C. Fraser, Nicholas Wrighton, Paul S. Myers, Gillian Kingsbury
  • Patent number: 6323334
    Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. In particular, the invention provides a nucleotide sequence which encodes a previously unknown human 103 gene product. The invention also provides expression vectors containing the nucleic acid molecules of the invention and host cells into which the expression vectors have been introduced. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: November 27, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Gillian A. Kingsbury, Kevin R. Leiby
  • Patent number: 5317088
    Abstract: Peptide fragments of conglutinin are provided for use in binding to complementary ligands. Particularly, an N-proximal region is provided having a hypervariable region with a collagen type structure for binding to complementary molecules, and a C-proximal region which provides for lectin binding activity.
    Type: Grant
    Filed: July 28, 1992
    Date of Patent: May 31, 1994
    Assignee: Applied Immune Sciences, Inc.
    Inventors: Young M. Lee, Kevin R. Leiby, Thomas B. Okarma